FDA clearance momentum Instylla recently announced FDA 510(k) clearance for the Tembo Embolic System, signaling a validated product pipeline and near-term commercial prospects. This provides a tangible entry point for clinical evangelists and distribution partners to pursue hospital systems and vascular centers seeking proven embolization solutions.

Leadership expansion New CEO Sean Boyle appointed in 2025 alongside a Board addition from Delos Capital enhances strategic execution and fundraising credibility. Sales teams can leverage leadership credibility to engage large hospital networks and secure executive sponsorship for pilot programs.

Funding confidence With $85M in funding and a current revenue range of $10–25M, Instylla demonstrates financial support to scale sales efforts, invest in field clinical education, and broaden distribution channels across peripheral vascular and interventional radiology markets.

Clinical momentum Renewed clinical activity and HALT Study enrollment highlight ongoing validation and real-world outcomes. This creates opportunities to partner with KOLs, present study data to interventional radiology departments, and accelerate adoption through evidence-based marketing.

Expansion-ready market A focused product line in liquid embolics for peripheral vascular embolization aligns with a sizable addressable market and a mix of mid-sized to larger healthcare systems. Target expansion through hospital networks, stocking distributors, and integrated IMED procurement programs to drive early installation and repeat usage.